Spyre Therapeutics Stock Surges This Past Year as $10.5 Million Buy Lifts Stake to $78 Million
2026-02-23 10:38:15 ET
Commodore Capital disclosed a buy of 400,161 shares of Spyre Therapeutics (NASDAQ:SYRE) , an estimated $10.46 million trade based on quarterly average pricing, per a February 17, 2026, SEC filing.
According to a February 17, 2026, SEC filing , Commodore Capital increased its position in Spyre Therapeutics by 400,161 shares during the fourth quarter. The estimated transaction value is $10.46 million, based on the mean unadjusted closing price for the period. The quarter-end value of the stake rose by $44.92 million, a figure that includes both share accumulation and stock price appreciation.
Spyre Therapeutics, Inc. is a biotechnology company focused on innovative antibody-based therapies for inflammatory bowel disease. With a pipeline of differentiated preclinical assets, the company leverages advanced biologic platforms to address unmet needs in ulcerative colitis and Crohn's disease. Its strategy centers on scientific innovation and targeted therapeutic development to establish a competitive position in the IBD treatment landscape.
NASDAQ: SYRE
SYRE Trading
1.62% G/L:
$40.73 Last:
195,554 Volume:
$40.92 Open:
